Evidence map›Paper›PMID 39591124›Full record

ArticleVaccines2024

The Impact of COVID-19 Vaccination and Infection on the Exacerbation of Myasthenia Gravis.

Yuting Jiang, Jingsi Wang, Shengyao Su, Shu Zhang, Qi Wen, Yaye Wang, Ling Li, Jianxin Han, Nairong Xie, Haoran Liu and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Yuting JiangDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Jingsi WangDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Shengyao SuDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Shu ZhangDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Qi WenDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Yaye WangDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Ling LiDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Jianxin HanDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Nairong XieDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Haoran LiuDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Yanan SunDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Yan LuDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Li DiDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Min WangDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Min XuDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Hai ChenDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Suobin WangDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Xinmei WenDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Wenjia ZhuDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Yuwei DaDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.

Funding

Clinical Cohort Study of Myasthenia Gravis, National Key R&D Program of China, Precision Medicine Project 2017YFC0907700National Natural Science Foundation of China 62171299, 82001352
6 · The paper itself

Abstract

objectivesMyasthenia Gravis (MG) is an autoimmune disorder that can exacerbate for various reasons, including vaccination and infection. This study aimed to investigate the safety of COVID-19 vaccines for MG patients, factors influencing MG exacerbation after COVID-19 infection (MECI), the course and prognosis of MECI, and the impact of COVID-19 vaccine on infected MG patients.

methodsPatients were enrolled from the MG database in the Department of Neurology, Xuanwu Hospital, Capital Medical University. Two questionnaires were administered to collect data concerning COVID-19 vaccination (questionnaire 1, Q1) and infection (questionnaire 2, Q2) during two distinct periods. MG exacerbation was defined as an increase of at least two points in the MG activity of daily living (MG-ADL) score. COVID-19 severity was categorized as "hospitalization" or "home management"; Results: During the first data-collecting period, our database registered 1013 adult patients: 273 (26.9%) had received COVID-19 vaccinations and completed Q1, and 8 (2.9%) experienced MG exacerbation after vaccination. During the second data-collecting period, among the newly registered patients, 366 patients completed Q2. Of these, 244 were infected, with 39 (16.0%) experiencing MECI and 21 (8.6%) requiring hospitalization. Multivariate analysis showed that generalized myasthenia gravis was associated with MECI (OR 3.354, 95% CI: 1.423-7.908,

Indexed as

COVID-19 infectionexacerbationmyasthenia gravisomicron variantsoutcomesvaccination

Identifiers

PMID39591124
PMCPMC11598725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.